Biogen blocking bid rejected; signs $2.4bn deal
28-02-2020
Amgen successfully blocks sale of Sandoz’s Zarxio biosimilar
07-05-2015
Castleski / Shutterstock.com
Taiwanese pharmaceutical company PharmaEssentia Corporation (PEC) has failed to convince a district court judge to throw out a €140 million award to AOP Orphan Pharmaceuticals (AOP).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
PharmaEssentia Corporation, AOP Orphan Pharmaceuticals, US District Court for the District of Massachusetts
